PAX7 shows high expression levels in breast cancer (BRCA), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), gastric adenocarcinoma (STAD), and thyroid cancer (THCA), while also being highly expressed in prostate adenocarcinoma (PRAD) and glioma (GBM). This evidence concerns the gene PAX7 and prostate adenocarcinoma.